Elos Medtech announces timeline for CEO transition
The Board of Directors of Elos Medtech has agreed the timeline of the transition with current CEO Jan Wahlström’s tenure ending in connection with Elos Medtech’s Annual General Meeting on May 03, 2022. While a search for Jan’s succession is underway, the Board appoints Jodie Gilmore, President & Business Unit Director Orthopedics, as interim Chief Executive Officer, and Søren Olesen President & Business Unit Director Dental, as interim deputy Chief Executive Officer. Jodie and Søren will assume their positions in connection with Elos Medtech’s Annual General Meeting on May 03, 2022 and will in parallel retain their current roles.
Both Jodie and Søren have over 30 years of experience in the industry and have successfully run their companies which are now part of the Group. In recent years, they have focused on strategic business development within each business area.
To ensure continuity during the transition period for the change of CEO, an Executive Committee has been appointed for Elos Medtech. This team consists of Jodie Gilmore, Søren Olesen and Ewa Linsäter, CFO.
The committee has been appointed to maintain the company's customer focus and growth, and thus continue in the same strategic direction during the transition period.
The Executive Committee will navigate Elos Medtech together with stability and confidence as of May 3, 2022, until a permanent CEO is in place.
The appointment of Jodie Gilmore is conditional on the Swedish Companies Registration Office granting an exemption from the CEO's residence requirement.
“We would again like to warmly thank Jan for his efforts as President and CEO of Elos Medtech and wish him all the best in the future”, says Lovisa Lander, Chairman of the Board.
About Elos Medtech
Elos Medtech is a leading development and production partner for medical devices and components, with a focus on dental and orthopedic implants and instruments. The company operates from facilities in Sweden, Denmark, China, and the U.S. The customer base comprises international medical technology companies.
Elos Medtech has more than 550 employees and a turnover of more than SEK 700 million. Elos Medtech has been listed on NASDAQ Stockholm AB since 1989. Elos Medtech’s B share is categorized as a Health Care company on the Mid Cap list.
Gothenburg, March 16, 2022
Elos Medtech AB (publ)
For further information, please contact:
Lovisa Lander, Chairman of the Board, +44 (0)20 7823 0211, e-post: llander@ta.com
For additional information about the Elos Medtech Group, visit www.elosmedtech.com
This is information that Elos Medtech AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on March 16, 2022, at 22:20 (CET).
Tags: